OrthoPreserve
Developing a meniscus implant for the treatment of persistent knee pain and prevention of arthritis.
Website: https://www.orthopreserve.com
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | OrthoPreserve |
| Tagline | Developing a meniscus implant for the treatment of persistent knee pain and prevention of arthritis |
| Headquarters | Henrico, VA, United States |
| Founded | 2021 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology Type | Biotech / Life Sciences (Medical Device) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2-3 named) |
| Funding Label | Seed |
Links
PUBLIC
- Website: https://www.orthopreserve.com
- LinkedIn (founder profile): https://www.linkedin.com/in/jonathanwschwartz/
- NIH SEED portfolio page: https://seed.nih.gov/portfolio/nih-portfolio-company-showcase/orthopreserve
- Crunchbase: https://www.crunchbase.com/organization/orthopreserve
Executive Summary
PUBLIC
OrthoPreserve is a Henrico, Virginia medical device startup developing a synthetic meniscus implant intended to treat persistent post-meniscectomy knee pain and delay the progression to osteoarthritis and total knee replacement [OrthoPreserve]. The company traces its origin to a graduate thesis project by co-founder and CEO Jonathan Schwartz, who carried the concept from a Georgia Tech engineering program into a clinical collaboration with orthopedic surgeon Dr. Cyrus Kump and physician assistant Max Guillot [Hypepotamus] [Georgia Tech, July 2024]. The core asset is a meniscus replacement device positioned as a less invasive alternative for patients who have exhausted conservative care but are not yet candidates for arthroplasty [OrthoPreserve]. In 2024, the device received FDA Breakthrough Device Designation, and the company reported enrollment in the FDA's Total Product Life Cycle Advisory Program (TAP), described in company materials as a first for an orthopedic device [ORTHOWORLD] [VirginiaBio]. Disclosed institutional backing includes Activation Capital, with non-dilutive support tied to NIH NIAMS funding [NIH SEED] [Crunchbase]. Headcount is small, with third-party trackers reporting between four and six employees, consistent with a pre-pivotal-trial medical device company [RocketReach]. Over the next 12 to 18 months, the items worth tracking are the design and initiation of a pivotal clinical study, any priced equity round to fund that study, and the build-out of regulatory and clinical leadership beyond the founding team.
Data Accuracy: GREEN -- Confirmed across OrthoPreserve, Georgia Tech, ORTHOWORLD, VirginiaBio, and the NIH SEED portfolio.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B (medical device sold into hospital and surgical channels) |
| Industry / Vertical | Healthtech / Orthopedics |
| Technology Type | Class III implantable medical device (Breakthrough Designation) |
| Geography | United States (HQ Henrico, VA; operating presence in Atlanta, GA) |
| Growth Profile | Venture Scale |
| Founding Team | Engineer-clinician trio (Schwartz, Kump, Guillot) |
| Funding | Seed plus NIH non-dilutive support |
Company Overview
PUBLIC
OrthoPreserve was founded in 2021 to commercialize a synthetic meniscus implant that originated in academic research. According to a CEO interview with Hypepotamus, Jonathan Schwartz developed the device concept during graduate work and brought the idea to Dr. Cyrus Kump, the orthopedic surgeon he was working with at the time; Kump and physician assistant Max Guillot recognized a clinical gap in their own practice for patients with persistent symptoms after meniscus injury or partial meniscectomy, and the three formed the company to advance the implant toward regulatory clearance [Hypepotamus]. Schwartz is a Georgia Tech alumnus, and the university has publicly profiled the company as an alumnus-founded medtech startup [Georgia Tech, July 2024].
The company is headquartered in Henrico, Virginia, and lists operating activity in both Atlanta, Georgia and Richmond, Virginia [Activation Capital] [NIH SEED]. It has been associated with the ATDC accelerator at Georgia Tech and the Frontier BioHealth Program, both of which support early-stage life science companies in the Southeast. RocketReach lists six employees, while an Activation Capital profile references a team of four; the discrepancy is consistent with a small organization adding contract regulatory and clinical roles around a core founding team [RocketReach] [Activation Capital].
The most material milestones to date are regulatory rather than commercial. In public statements during 2024, the company announced FDA Breakthrough Device Designation for its meniscus implant and enrollment in the FDA's TAP program, with company communications describing the TAP enrollment as the first for an orthopedic device [ORTHOWORLD] [VirginiaBio]. The company also appears in the NIH SEED portfolio under the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), indicating federal non-dilutive support for the underlying research and development program [NIH SEED].
Data Accuracy: GREEN -- Confirmed by Hypepotamus, Georgia Tech, ORTHOWORLD, VirginiaBio, NIH SEED, and Crunchbase.
Product and Technology
MIXED
The product is a synthetic meniscus implant intended for patients with persistent symptomatic meniscus dysfunction, a population the company describes as poorly served by conservative care and not yet appropriate for total knee replacement [PUBLIC] [OrthoPreserve]. Company materials frame the clinical objective in two parts: relieve pain and restore function in the near term, and preserve articular cartilage to delay the onset of osteoarthritis and the eventual need for arthroplasty [PUBLIC] [OrthoPreserve, Mission page]. The implant is positioned as a less invasive alternative to knee replacement, intended to fit into the existing arthroscopic surgical workflow used by orthopedic sports medicine specialists [PUBLIC] [OrthoPreserve, Meniscus Replacement page].
From a regulatory standpoint, the device sits in a Class III pathway typical of permanent orthopedic implants. The FDA Breakthrough Device Designation, confirmed by ORTHOWORLD's reporting and a quote attributed to Schwartz, signals that FDA has agreed the device addresses a serious condition with no satisfactory alternative and qualifies for expedited review interactions [PUBLIC] [ORTHOWORLD]. The reported TAP enrollment, if accurate as the first orthopedic enrollee, would give the company structured early engagement with FDA, CMS, and payer stakeholders during development, which historically has been used by cardiovascular and neurology Breakthrough devices [MIXED] [PRNewswire via VirginiaBio].
Specific design details (polymer chemistry, fixation method, sizing range, surgical instrumentation) are not described publicly in a way that can be cited from the captured sources, and the company has not announced pivotal clinical trial enrollment or geographic CE-mark plans [PUBLIC]. Investors evaluating the technology should expect that material technical and clinical data will sit in regulatory submissions and conference abstracts rather than on the website.
Data Accuracy: GREEN -- Product positioning confirmed across OrthoPreserve, ORTHOWORLD, and VirginiaBio; technical detail intentionally limited.
Market Research and Opportunity
PUBLIC
The meniscus is the most commonly injured structure in the knee, and the consequences of losing meniscal tissue are a well-established driver of downstream osteoarthritis and joint replacement, which is what makes a durable meniscus replacement clinically interesting now. The published clinical literature has long documented that partial meniscectomy patients face elevated rates of cartilage degeneration over the following decade, and the orthopedic industry has invested in repair augmentation, allograft transplantation, and synthetic scaffolds in response. OrthoPreserve sits within that synthetic implant segment, alongside a small number of named competitors discussed in the next section.
The captured research set does not include a third-party TAM figure specific to meniscus replacement that can be cited here without speculation. As an analogous reference point, the broader knee reconstruction and arthroplasty market is a multi-billion-dollar global category dominated by large strategics (Stryker, Zimmer Biomet, Johnson and Johnson MedTech, Smith and Nephew), and meniscus-preserving devices are typically discussed as an upstream segment that could divert a portion of patients who would otherwise progress to partial or total knee replacement. Specific dollar sizing for the meniscus implant subsegment is not publicly available in the sources captured for this report.
The most credible near-term demand drivers are demographic and clinical. The patient pool of post-meniscectomy adults with persistent pain is large and growing as sports participation and activity levels in middle-aged adults rise, and surgeons increasingly favor cartilage- and meniscus-preserving strategies over aggressive resection. Regulatory tailwinds matter as well: FDA Breakthrough Device Designation creates a clearer path to expedited review interactions, and TAP enrollment, if it functions as designed, accelerates payer and coverage conversations in parallel with clinical development [ORTHOWORLD] [VirginiaBio]. The principal macro headwind is reimbursement: novel orthopedic implants without an existing CPT code or established coverage policy face slow adoption curves even after PMA approval, and the path from approval to broad coverage frequently takes additional years.
| Sizing claim | Value | Source |
|---|---|---|
| FDA Breakthrough Device Designation granted | Yes | [ORTHOWORLD] |
| TAP enrollment, reported first for an orthopedic device | Yes (company-reported) | [VirginiaBio] |
| NIH NIAMS-funded research program | Yes | [NIH SEED] |
Analyst takeaway: the cited evidence supports a strong regulatory narrative and a clear clinical unmet need, but a defensible market sizing for the meniscus replacement subsegment specifically is not publicly available in the captured research and should be requested from the company.
Data Accuracy: YELLOW -- Regulatory milestones confirmed by ORTHOWORLD and VirginiaBio; market sizing not publicly available at the segment level.
Competitive Landscape
MIXED
OrthoPreserve is competing in a narrow but strategically important slice of orthopedics where a handful of dedicated meniscus implant developers sit between large joint reconstruction incumbents on one side and biologic repair approaches on the other.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| OrthoPreserve | Synthetic meniscus implant for post-meniscectomy patients | Seed; FDA Breakthrough + TAP | Engineer-clinician founding trio; reported first orthopedic TAP enrollee | [PUBLIC] [ORTHOWORLD] [VirginiaBio] |
| Active Implants (NUsurface) | Polycarbonate-urethane meniscus implant; long-running US clinical program | Private, multiple rounds historically | Largest accumulated clinical dataset in synthetic meniscus replacement | [MIXED] [structured facts] |
| Orteq Ltd (Actifit) | Polyurethane meniscal scaffold for partial defects | Private; CE-marked in Europe | European commercial footprint; scaffold rather than full replacement | [MIXED] [structured facts] |
| Stryker | Global orthopedic strategic; full knee portfolio | Public (NYSE: SYK) | Distribution, sales force, and acquisition capacity across knee preservation and replacement | [MIXED] [structured facts] |
The segment map breaks into three buckets. The first is the dedicated meniscus replacement and scaffold developers (Active Implants, Orteq, OrthoPreserve), all attempting to convert a clinical need into a durable, reimbursable implant. The second is biologic and repair-augmentation approaches (suture-based repair systems, allograft meniscus transplantation, and emerging cell or scaffold biologics), which compete for the same patient at an earlier point in the care pathway. The third is the large knee reconstruction strategics (Stryker, Zimmer Biomet, Johnson and Johnson MedTech, Smith and Nephew), who do not currently field a comparable synthetic meniscus product but who own the surgeon relationships, the distribution, and the acquisition checkbook that any approved meniscus implant will eventually need.
Where OrthoPreserve has a defensible edge today, it is on regulatory positioning and clinical fit. The combination of Breakthrough Designation and reported TAP enrollment is uncommon for a seed-stage orthopedic company and signals that FDA views the unmet need as serious [ORTHOWORLD] [VirginiaBio]. The engineer-clinician founding structure (Schwartz on engineering, Kump on surgical practice, Guillot on clinical workflow) is the kind of team composition that typically produces implant designs that surgeons are willing to actually use [Georgia Tech, July 2024] [Hypepotamus]. That edge is partially perishable: regulatory designations narrow the gap to approval but do not guarantee it, and a competitor with a stronger pivotal dataset can leapfrog a designation advantage.
Where OrthoPreserve is most exposed is on accumulated clinical evidence and capital depth. Active Implants has been pursuing US approval for the NUsurface device for years and has generated a clinical evidence base that a seed-stage company cannot match in the near term. Stryker and the other large strategics own the surgeon channel into which any approved implant must sell, which means commercialization will almost certainly require either a partnership or an acquisition rather than an independent sales build. The most plausible 18-month competitive scenario: winner if OrthoPreserve converts Breakthrough and TAP into a well-designed, adequately funded pivotal trial and uses TAP engagement to pre-negotiate a coverage pathway; loser if a better-capitalized competitor reaches PMA approval first and locks in early CPT and coverage decisions that constrain follow-on entrants.
Data Accuracy: YELLOW -- Competitor identities confirmed in structured facts; comparative funding and stage detail drawn from general industry knowledge and not independently re-verified for this report.
Opportunity
PUBLIC
If the implant clears its pivotal trial and secures coverage, the prize is becoming the default surgical option for a patient population that today has no good answer between arthroscopic debridement and total knee replacement.
The headline opportunity. The single largest outcome OrthoPreserve could plausibly achieve is establishing the category-defining synthetic meniscus implant in the United States: a device that orthopedic sports medicine surgeons reach for when a patient has failed conservative care, has had prior meniscectomy, and is too young or too active for arthroplasty. The cited evidence makes that outcome reachable rather than aspirational on three grounds. First, FDA has formally agreed the unmet need is serious enough to warrant Breakthrough Designation [ORTHOWORLD]. Second, the company has reportedly entered TAP, which is structurally designed to compress the time between approval and reimbursement [VirginiaBio]. Third, the founding team combines the engineering origin of the device with practicing orthopedic clinicians who experience the unmet need in their own clinic [Hypepotamus] [Georgia Tech, July 2024]. None of those facts guarantees approval, but together they describe a credible path.
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Independent PMA and strategic partnership | OrthoPreserve completes pivotal trial, secures PMA, and partners with a large knee strategic for distribution | A successful pivotal readout and a co-marketing or distribution deal with a Stryker-class incumbent | Large strategics have repeatedly acquired or partnered with single-product orthopedic implant companies post-approval [MIXED] [industry pattern, structured facts list Stryker as a competitor] |
| Acquisition by a knee reconstruction strategic | A large orthopedic company acquires OrthoPreserve before or shortly after approval to add a meniscus-preserving asset to its knee portfolio | Pivotal data plus the scarcity value of a Breakthrough-designated meniscus implant | Breakthrough Designation is a known driver of strategic interest in implantable devices [ORTHOWORLD] |
| Coverage-led adoption via TAP | TAP engagement produces an early, clear coverage pathway, and surgeon adoption ramps quickly post-approval because reimbursement is already in place | TAP-driven payer alignment ahead of PMA approval | TAP is explicitly designed to align FDA, CMS, and private payers earlier in development [VirginiaBio] |
What compounding looks like. In implantable orthopedics, the flywheel is clinical evidence plus surgeon habit. Each implanted patient generates outcomes data that strengthens the next round of payer negotiations, conference presentations, and surgeon training; surgeons who train on a device early tend to remain users, and key-opinion-leader adoption at major sports medicine programs cascades into community practice. For OrthoPreserve, the early compounding loop is regulatory: Breakthrough Designation attracts pivotal-trial sites, pivotal-trial sites generate the clinical evidence that supports PMA and coverage, and PMA plus coverage opens the surgeon channel. The captured evidence shows the first turn of that flywheel (designation and TAP) is underway [ORTHOWORLD] [VirginiaBio].
The size of the win. A useful comparable, though not a forecast, is the broader category of single-product orthopedic implant companies acquired by large strategics in recent years, where transaction values have ranged from the low hundreds of millions to over a billion dollars depending on clinical data quality and market readiness. If OrthoPreserve reaches PMA with a clean pivotal dataset and an established coverage pathway, an outcome in that range is the relevant reference frame (scenario, not a forecast). If the device additionally becomes the standard of care for post-meniscectomy patients, the long-run revenue base scales with the population of US adults who today fall into the gap between arthroscopy and arthroplasty, a population large enough to anchor a meaningful franchise inside any major knee portfolio.
Data Accuracy: YELLOW -- Regulatory catalysts confirmed; scenario valuations drawn from analogous transaction patterns and explicitly labelled as scenarios rather than forecasts.
Sources
PUBLIC
[OrthoPreserve] OrthoPreserve: Meniscus Implant for Knee Pain Treatment | https://www.orthopreserve.com
[OrthoPreserve] Mission | https://www.orthopreserve.com/mission
[OrthoPreserve] Meniscus Replacement | https://www.orthopreserve.com/meniscus-implant
[OrthoPreserve] Technology | https://www.orthopreserve.com/technology
[NIH SEED] OrthoPreserve NIH Portfolio Company Showcase | https://seed.nih.gov/portfolio/nih-portfolio-company-showcase/orthopreserve
[Crunchbase] OrthoPreserve Company Profile and Funding | https://www.crunchbase.com/organization/orthopreserve
[Crunchbase] OrthoPreserve Financial Details | https://www.crunchbase.com/organization/orthopreserve/financial_details
[RocketReach] OrthoPreserve Information | https://rocketreach.co/orthopreserve-profile_b6c8ad26c763d567
[RocketReach] OrthoPreserve Management Team and Org Chart | https://rocketreach.co/orthopreserve-management_b6c8ad26c763d567
[Hypepotamus] CEO Q&A: How A Graduate Thesis Turned Into MedTech Startup OrthoPreserve | https://hypepotamus.com/news/ceo-qa-how-a-graduate-thesis-turned-into-medtech-startup-orthopreserve/
[ORTHOWORLD] OrthoPreserve Gains Breakthrough Designation for Meniscus Implant | https://www.orthoworld.com/orthopreserve-gains-breakthrough-designation-for-meniscus-implant/
[VirginiaBio] OrthoPreserve Receives FDA Breakthrough Device Designation and TAP Enrollment | https://www.vabio.org/orthopreserve-receives-both-fda-breakthrough-device-designation-and-prestigious-tap-enrollment-for-meniscus-implant-to-rework-knee-pain-treatment/
[LinkedIn] Jonathan Schwartz - OrthoPreserve | https://www.linkedin.com/in/jonathanwschwartz/
[Georgia Tech, July 2024] Tech Alum Launches Meniscus Implant Startup, News Center | https://news.gatech.edu/news/2024/07/11/tech-alum-launches-meniscus-implant-startup
[Georgia Tech Research, July 2024] Tech Alum Launches Meniscus Implant Startup, Research | https://research.gatech.edu/tech-alum-launches-meniscus-implant-startup
Articles about OrthoPreserve
- OrthoPreserve Is Building a Meniscus Implant to Keep Knees Out of the Operating Room — The Henrico, Virginia startup has FDA Breakthrough status and a TAP slot for a device aimed at patients too young for a total knee replacement.